Diaccurate is a clinical stage biotech developing a next generation precision cancer therapies to cure patients from incurable diseases. Its most advanced compound DIACC3010 optimally inhibits S6K, a kinase involved in many cancers as metastatic breast cancer, glioblastoma or gastric cancer. Licensed from Merck KGaA, it has demonstrated promising clinical efficacy signals in Phase I and will enter Phase II in 2023. Its second project DIACC2010 refers to the development of the only molecule known to inhibit KIF20A (a kinesin involved in the proliferation of cancer cells) while non toxic for normal cells. Its mode of action makes it a privileged candidate to become a new payload for the ADCs (Antibody Drug Conjugates) which is a new technology presently revolutionizing cancer treatment. Diaccurate relies on a experienced management team and is supported by an international Scientific and Medical Board composed by world first class experts.
See website
Management team
In summary
Diaccurate is a clinical stage biotech developing a next generation precision cancer therapies to cure patients from incurable diseases
They talk about it
We think we could have proof of concept in HIV population. Then we will investigate which tumor we can apply it to.
It does not respond to current immunotherapy and it’s a terrible disease. We have preliminary data that say we should continue working down that line
News
